| CAS NO: | 260553-97-7 |
| 包装 | 价格(元) |
| 10 mM * 1 mL in DMSO | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 生物活性 | TM-25659 is atranscriptional co-activator with PDZ-binding motif (TAZ)modulator. Anti-osteoporotic and anti-obesity activities[1]. | ||||||||||||||||
| IC50& Target | TAZ[1] | ||||||||||||||||
| 体外研究 (In Vitro) | TM-25659 (2, 10, 20, 100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ[1]. TM-25659 (2, 10, 50 μM) enhances osteogenic gene expression and thereby increases osteoblast differentiation[1]. Cell Proliferation Assay[1]
| ||||||||||||||||
| 体内研究 (In Vivo) | TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone lossin vivoand decreases weight gain in an obesity model[1]. TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t1/2of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h-1×kg-1and the volume of distribution at steady-state (1.91 L×h-1×kg-1) is larger than the volume of total body fluids[1].
| ||||||||||||||||
| 分子量 | 500.60 | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| Formula | C30H28N8 | ||||||||||||||||
| CAS 号 | 260553-97-7 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 溶解性数据 | In Vitro: DMSO : ≥ 135 mg/mL(269.68 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
